Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1954
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

GlaxoSmithKline